文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.

作者信息

Steffel Jan, Collins Ronan, Antz Matthias, Cornu Pieter, Desteghe Lien, Haeusler Karl Georg, Oldgren Jonas, Reinecke Holger, Roldan-Schilling Vanessa, Rowell Nigel, Sinnaeve Peter, Vanassche Thomas, Potpara Tatjana, Camm A John, Heidbüchel Hein

机构信息

Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich, Switzerland.

Age-Related Health Care, Tallaght University Hospital / Department of Gerontology Trinity College, Dublin, Ireland.

出版信息

Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.

DOI:10.1093/europace/euab065
PMID:33895845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11636576/
Abstract
摘要

相似文献

[1]
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.

Europace. 2021-10-9

[2]
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.

Future Cardiol. 2022-5

[3]
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.

Eur J Epidemiol. 2018-6-8

[4]
Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population.

Adv Ther. 2025-3

[5]
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Thromb Haemost. 2014-5-5

[6]
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.

Stroke. 2018-12

[7]
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Stroke. 2017-7-17

[8]
Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.

Int J Cardiol. 2024-6-1

[9]
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.

Medicine (Baltimore). 2020-7-2

[10]
Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study.

PLoS One. 2024

引用本文的文献

[1]
Oral Anticoagulant Therapy in Patients with Atrial Fibrillation After Intracranial Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.

Clin Appl Thromb Hemost. 2025

[2]
Measurement of plasma direct oral anticoagulants concentrations in real-world clinical and laboratory settings on a 24/7 basis: a 10-year experience.

J Thromb Thrombolysis. 2025-8-19

[3]
Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications.

J Clin Med. 2025-8-7

[4]
Anti-Factor Xa Activity of Apixaban in Extremely Low Body Weight.

J Clin Med. 2025-7-24

[5]
Practical Comprehensive Approach to Current Atrial Fibrillation Challenges: Insights from an Expert Panel.

J Clin Med. 2025-7-22

[6]
Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources.

Pharmaceuticals (Basel). 2025-7-16

[7]
Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis.

Front Pharmacol. 2025-7-14

[8]
Identification of risk factors and development of a predictive model in patients using cefmetazole for international normalized ratio elevation.

PLoS One. 2025-7-28

[9]
Serum Concentration of Apixaban in Relation to Renal Function in Older Hospitalized Patients.

Drugs Aging. 2025-7-24

[10]
The Use of Direct Oral Anticoagulants (DOACs) in the Geriatric Population-How to Overcome the Challenges of Geriatric Syndromes.

J Clin Med. 2025-6-20

本文引用的文献

[1]
Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19.

J Arrhythm. 2020-12-11

[2]
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.

J Am Coll Cardiol. 2021-3-9

[3]
Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis.

Thromb J. 2021-2-1

[4]
Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis.

Heart. 2021-3

[5]
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.

N Engl J Med. 2020-11-14

[6]
Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study.

Am J Cardiovasc Drugs. 2021-5

[7]
Direct oral anticoagulant use in left ventricular thrombus.

Thromb J. 2020-10-29

[8]
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR.

JACC Cardiovasc Interv. 2020-11-23

[9]
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.

Eur Heart J Cardiovasc Pharmacother. 2021-4-9

[10]
Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures.

Eur Heart J Suppl. 2020-9-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索